Updated Healthcare Common Procedure Coding System Code (HCPCS) and dose descriptor for Amgen’s Neulasta® (pegfilgrastim) Onpro® and Neulasta®

Neulasta® (pegfilgrastim) Onpro® and Neulasta® have an updated Healthcare Common Procedure Coding System (HCPCS) Code and dose descriptor, effective January 1, 2022.


The UPDATED DOSE DESCRIPTOR is Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

This updated dose descriptor can be billed in multiple units to accommodate a variety of doses. Providers should note the new dose descriptor is now 0.5 mg. Per label, the dose for Neulasta® (pegfilgrastim) is 6 mg. Please accurately report service units when billing.

Key dates:

  • For dates of service on and after January 1, 2022, providers must use the updated HCPCS Code J2506, and dose descriptor, and discontinue use of the HCPCS Code J2505, as it will no longer be accepted
  • Providers may only use J2505 for dates of service on or before December 31, 2021

Information on the updated code and dose descriptor is summarized in the following attachments:

Neulasta® (pegfilgrastim) Onpro® and Neulasta® J-Code Flashcard, which contains the effective date, coding, and support service information and Neulasta® (pegfilgrastim) Onpro® and Neulasta® Billing and Coding Guide, which will provide you with detailed coding, dosing and administration, and support service information.

Hospital Outpatient Coding and Billing Information Sheet

Physician Office Coding and Billing Information Sheet

Please see full Prescribing Information for Neulasta® (pegfilgrastim) Onpro® and Neulasta® by clicking the link below:

Neulasta® Prescribing Information